NewMed Medical Technologies Listed in GEI China's Potential Unicorn Enterprise Report 2024

Unicorn refers to a start-up enterprise with attributes such as rapid development, rarity, and being highly favored by investors. Potential unicorns, as the reserve force of unicorn enterprises, play a more crucial role in leading scientific and technological innovation, exploring new fields and tracks, and shaping new drivers and advantages for development. They are also a typical representation of new quality productivity and an important indicator for measuring regional innovation vitality.

The report shows that the frontier technology attributes of potential unicorn companies are prominent. In China's potential unicorn companies, those in the frontier technology sector account for over 85%. Nearly 20% of potential unicorn companies are specialized and sophisticated "little giant" enterprises, and nearly 60% are national high-tech enterprises.

NewMed's inclusion in this list not only demonstrates the capital market and industry's high recognition of the broad development prospects of China-produced interventional valve devices, but also fully proves NewMed's breakthrough innovation capabilities and forward-looking market expansion abilities.

Since its establishment in 2015, NewMed has been focusing on the research and development as well as the industrialization of interventional artificial heart valve systems at an internationally advanced level. It provides comprehensive innovative solutions for interventional valve treatment that are leading in China, gradually growing into one of the top companies in China’s interventional valve medical device industry. Currently, NewMed's product portfolio includes mitral valve replacement and repair, aortic valve replacement, tricuspid valve replacement and repair, pulmonary valve replacement, as well as auxiliary devices such as balloon dilation catheters and expandable sheaths, making it one of the companies with the broadest range of interventional valve treatment products in China.

NewMed has also independently developed and refined a comprehensive technology platform that is among the leading in China, covering all the necessary research and development needs in the field of cardiac valves. This includes platforms for medical metal materials, medical polymer materials, biological tissue, and large balloon catheters, among others. These major technology platforms are interdependent and mutually reinforcing, and can be applied to almost all products in NewMed's portfolio, laying a solid foundation for the steady progress of existing R&D projects and the continuous expansion of the product pipeline.

To maintain a continuous source of innovation, NewMed, based on its extensive experience in new product R&D and industrialization, has established the "NewMed Singularity Innovation Center." This center integrates resources from the government, funds, large enterprises, research institutes and universities, and hospitals to form an international and professional innovation platform that synergizes "government, industry, academia, research, medical, and investment" collaboration. It aims to overcome "bottleneck" technologies and continuously incubate various cutting-edge innovative medical technology products.

Being selected for the list of China's potential unicorn enterprises is, for NewMed, both an affirmation of past achievements and an encouragement for future endeavors. We will take this as an opportunity to further increase R&D investment, deepen industry-university-research-medical cooperation, continuously optimize product performance, overcome industry challenges, and keep injecting more vitality into China's valve interventional technology field. We aim to benefit more valve disease patients and strive to realize the wonderful vision of "Healthy China."